Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 14
2022
|
Michael J. Davidoff SVP, Payer Business |
BUY
Grant, award, or other acquisition
|
Direct |
35,161
+22.93%
|
-
|
|
Jan 14
2022
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
22,503
+23.47%
|
-
|
|
Jan 11
2022
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,750
+6.34%
|
$0
$0.84 P/Share
|
|
Jan 07
2022
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,270
+6.95%
|
$168,540
$2.03 P/Share
|
|
Jan 06
2022
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
30,950
+5.55%
|
$154,750
$5.82 P/Share
|
|
Dec 31
2021
|
Chaim Indig Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
255,000
-19.64%
|
-
|
|
Dec 31
2021
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
137
+0.17%
|
$4,795
$35.41 P/Share
|
|
Dec 31
2021
|
Randy Rasmussen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
342
+0.44%
|
$11,970
$35.41 P/Share
|
|
Dec 31
2021
|
Michael J. Davidoff SVP, Payer Business |
BUY
Exercise of conversion of derivative security
|
Direct |
6,399
+7.16%
|
$25,596
$4.71 P/Share
|
|
Dec 09
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+3.71%
|
$100,000
$2.03 P/Share
|
|
Dec 09
2021
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.66%
|
$0
$0.84 P/Share
|
|
Nov 09
2021
|
Randy Rasmussen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,185
-8.54%
|
$524,505
$73.98 P/Share
|
|
Nov 08
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,499
-1.06%
|
$112,425
$75.12 P/Share
|
|
Nov 08
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
1,499
+1.05%
|
$5,996
$4.71 P/Share
|
|
Nov 06
2021
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,862
-3.29%
|
$208,926
$73.81 P/Share
|
|
Nov 05
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
3,478
-2.42%
|
$260,850
$75.15 P/Share
|
|
Nov 05
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
3,478
+2.36%
|
$13,912
$4.71 P/Share
|
|
Nov 01
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
5,451
-1.89%
|
$381,570
$70.83 P/Share
|
|
Nov 01
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
5,451
+3.6%
|
$21,804
$4.71 P/Share
|
|
Oct 29
2021
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.43%
|
$8,680
$70.54 P/Share
|
|
Oct 29
2021
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.86%
|
$8,680
$70.54 P/Share
|
|
Oct 15
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
5,452
-3.74%
|
$354,380
$65.36 P/Share
|
|
Oct 15
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
5,452
+3.6%
|
$21,808
$4.71 P/Share
|
|
Oct 01
2021
|
Ramin Sayar Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,797
+39.66%
|
-
|
|
Sep 01
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
4,978
-1.15%
|
$348,460
$70.56 P/Share
|
|
Sep 01
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
4,978
+3.31%
|
$19,912
$4.71 P/Share
|
|
Aug 31
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
474
-0.34%
|
$33,654
$71.84 P/Share
|
|
Aug 31
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
474
+0.34%
|
$1,896
$4.71 P/Share
|
|
Aug 30
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
54,672
-1.41%
|
$3,881,712
$71.71 P/Share
|
|
Aug 30
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,672
+2.08%
|
$328,032
$6.37 P/Share
|
|
Aug 27
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,556
-1.11%
|
$4,086,476
$71.92 P/Share
|
|
Aug 27
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,556
+4.22%
|
$230,224
$4.71 P/Share
|
|
Aug 27
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
21,455
-3.45%
|
$1,523,305
$71.89 P/Share
|
|
Aug 27
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
21,455
+11.71%
|
$42,910
$2.55 P/Share
|
|
Aug 26
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
800
-0.06%
|
$56,000
$70.05 P/Share
|
|
Aug 26
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+0.06%
|
$3,200
$4.71 P/Share
|
|
Aug 26
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
800
-0.57%
|
$56,000
$70.07 P/Share
|
|
Aug 26
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+0.56%
|
$1,600
$2.55 P/Share
|
|
Aug 25
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
600
-0.05%
|
$42,000
$70.03 P/Share
|
|
Aug 25
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+0.05%
|
$2,400
$4.71 P/Share
|
|
Aug 25
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
500
-0.35%
|
$35,000
$70.04 P/Share
|
|
Aug 25
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+0.35%
|
$1,000
$2.55 P/Share
|
|
Aug 25
2021
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,082
-2.48%
|
$143,658
$69.05 P/Share
|
|
Aug 24
2021
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
2,577
-2.98%
|
$177,813
$69.54 P/Share
|
|
Aug 06
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,660
-0.13%
|
$116,200
$70.53 P/Share
|
|
Aug 06
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,660
+0.13%
|
$6,640
$4.71 P/Share
|
|
Aug 05
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,120
-2.2%
|
$1,968,400
$70.27 P/Share
|
|
Aug 05
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,120
+2.16%
|
$112,480
$4.71 P/Share
|
|
Aug 05
2021
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
8,236
-4.7%
|
$576,520
$70.13 P/Share
|
|
Aug 05
2021
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,236
+4.49%
|
$16,472
$2.03 P/Share
|